LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Public ClinicalTrials.gov record NCT03449108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Study identification
- NCT ID
- NCT03449108
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Bone Sarcoma
- Dedifferentiated Chondrosarcoma
- Giant Cell Tumor of Bone
- Malignancy in Giant Cell Tumor of Bone
- Malignant Solid Neoplasm
- Ovarian Carcinosarcoma
- Platinum-Resistant Ovarian Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Osteosarcoma
- Recurrent Ovarian Carcinoma
- Refractory Osteosarcoma
- Soft Tissue Sarcoma
- Thyroid Gland Anaplastic Carcinoma
- Thyroid Gland Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
- Aldesleukin Biological
- Autologous Tumor Infiltrating Lymphocytes LN-145 Biological
- Autologous Tumor Infiltrating Lymphocytes LN-145-S1 Biological
- Cyclophosphamide Drug
- Fludarabine Drug
- Ipilimumab Biological
- Nivolumab Biological
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2018
- Primary completion
- Apr 29, 2027
- Completion
- Apr 29, 2027
- Last update posted
- Nov 20, 2025
2018 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03449108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03449108 live on ClinicalTrials.gov.